Myasthenia Gravis and Thymoma

Myasthenia gravis is an autoimmune disease in which the body produces antibodies—most commonly against acetylcholine receptors, and in a significant minority of patients against MuSK—that disrupt transmission at the neuromuscular junction, causing fluctuating muscle weakness that can range from drooping eyelids to life-threatening respiratory failure. A striking proportion of patients harbor a thymoma or other thymic abnormality, and surgical removal of the thymus (thymectomy) can meaningfully improve outcomes, though the precise mechanisms linking thymic pathology to autoantibody production remain an active area of investigation. Researchers are working to understand why patients with different antibody profiles follow distinct clinical courses and respond differently to immunotherapies, as well as how to better classify thymic tumors in ways that predict both oncological prognosis and the likelihood of neurological remission. Improved epidemiological data and emerging biological therapies—including complement inhibitors and neonatal Fc receptor blockers—are reshaping how clinicians think about long-term disease management across these heterogeneous patient subgroups.

Works

70,384

Total citations

637,865

Keywords

Myasthenia GravisThymic TumorsAutoantibodiesMuSK AntibodiesThymectomyEpidemiology